{
  "url": "https://openlegislation.uk/eu-decision-2007-211/annex-I",
  "json_url": "https://openlegislation.uk/eu-decision-2007-211/annex-I.json",
  "legislation": "eudn/2007/211",
  "legislation_title": "Commission decision of 27 March 2007 on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2007 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council (notified under document number C(2007) 1285) (Only the Danish, Dutch, English, Estonian, French, German, Italian, Slovenian and Spanish texts are authentic) (Text with EEA relevance) (2007/211/EC)",
  "legislation_url": "https://openlegislation.uk/eu-decision-2007-211",
  "path": "annex/I",
  "kind": "annex",
  "number": "I",
  "heading": null,
  "text": "Pursuant to paragraph 3 of Decision XII/2 of the Twelfth Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), the following countries have determined that, due to the presence of suitable non-CFC MDIs, CFCs no longer qualify as ‘essential’ under the Protocol when combined with following active ingredients:\nTable 1\nShort acting beta agonist bronchodilators\nCountry\nSalbutamol\nTerbutaline\nFenoterol\nOrciprenaline\nReproterol\nCarbuterol\nHexoprenaline\nPirbuterol\nClenbuterol\nBitolterol\nProcaterol\nAustria\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nBelgium\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nCyprus\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nCzech Republic\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nDenmark\nX\nEstonia\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nFinland\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nFrance\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nGermany\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nGreece\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nHungary\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nIreland\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nItaly\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nLatvia\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nLithuania\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nLuxembourg\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nMalta\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nNetherlands\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nPoland\nX\nPortugal\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nNorway\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nSlovakia\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nSlovenia\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nSpain\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nSweden\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nUnited Kingdom\nX\nTable 2\nInhaled steroids\nCountry\nBeclomethasone\nDexamethasone\nFlunisolide\nFluticasone\nBudesonide\nTriamcinolone\nAustria\nX\nX\nX\nX\nX\nX\nBelgium\nX\nX\nX\nX\nX\nX\nCyprus\nCzech Republic\nX\nX\nX\nX\nX\nX\nDenmark\nX\nX\nEstonia\nX\nX\nX\nX\nX\nX\nFinland\nX\nX\nFrance\nX\nX\nGermany\nX\nX\nX\nX\nX\nX\nGreece\nHungary\nX\nX\nX\nX\nX\nX\nIreland\nX\nX\nItaly\nX\nX\nX\nX\nX\nX\nLatvia\nX\nX\nX\nX\nX\nX\nLithuania\nX\nX\nX\nX\nX\nX\nLuxembourg\nX\nX\nX\nX\nX\nX\nMalta\nX\nX\nPoland\nPortugal\nX\nX\nX\nThe Netherlands\nX\nX\nX\nX\nX\nX\nNorway\nSlovakia\nX\nX\nX\nX\nX\nX\nSlovenia\nX\nX\nX\nX\nX\nX\nSpain\nX\nX\nSweden\nX\nX\nUnited Kingdom\nX\nTable 3\nNon steroidal anti inflammatories\nCountry\nCromoglicic acid\nNedrocromil\nAustria\nX\nX\nBelgium\nX\nX\nCyprus\nX\nX\nCzech Republic\nX\nX\nDenmark\nX\nX\nEstonia\nX\nX\nFinland\nX\nX\nFrance\nX\nX\nGermany\nX\nX\nGreece\nX\nX\nHungary\nX\nIreland\nItaly\nX\nX\nLatvia\nX\nX\nLithuania\nX\nX\nLuxembourg\nX\nMalta\nX\nX\nPoland\nPortugal\nX\nThe Netherlands\nX\nX\nNorway\nSlovakia\nX\nX\nSlovenia\nX\nX\nSpain\nX\nSweden\nX\nX\nUnited Kingdom\nTable 4\nAnticholinergic bronchodilators\nCountry\nIpratropium bromide\nOxitropium Bromide\nAustria\nX\nX\nBelgium\nX\nX\nCyprus\nX\nX\nCzech Republic\nX\nX\nDenmark\nX\nX\nEstonia\nX\nX\nFinland\nX\nX\nFrance\nGermany\nX\nX\nGreece\nX\nX\nHungary\nX\nX\nIreland\nX\nX\nItaly\nLatvia\nX\nX\nLithuania\nX\nX\nLuxembourg\nX\nX\nMalta\nX\nX\nNetherlands\nX\nX\nPoland\nPortugal\nX\nNorway\nSlovakia\nX\nX\nSlovenia\nX\nX\nSpain\nX\nX\nSweden\nX\nX\nUnited Kingdom\nX\nX\nTable 5\nLong acting beta agonist bronchodilators\nCountry\nFormoterol\nSalmeterol\nAustria\nX\nX\nBelgium\nX\nX\nCyprus\nX\nCzech Republic\nX\nX\nDenmark\nEstonia\nX\nX\nFinland\nX\nX\nFrance\nX\nX\nGermany\nX\nX\nGreece\nHungary\nX\nX\nIreland\nX\nX\nItaly\nX\nX\nLatvia\nX\nX\nLithuania\nX\nX\nLuxembourg\nX\nX\nMalta\nX\nX\nNetherlands\nX\nPoland\nPortugal\nNorway\nSlovakia\nX\nX\nSlovenia\nX\nX\nSpain\nX\nSweden\nX\nX\nUnited Kingdom\nTable 6\nCombinations of active ingredients in a single MDI\nCountry\nAustria\nX All products\nBelgium\nX All products\nCyprus\nCzech Republic\nX All products\nDenmark\nEstonia\nFinland\nX All products\nFrance\nX All products\nGermany\nX All products\nGreece\nHungary\nX All products\nIreland\nItaly\nBudesonide + Fenoterol\nFluticasone + Salmeterol\nLatvia\nX All products\nLithuania\nX All products\nLuxembourg\nX All products\nMalta\nX All products\nNetherlands\nPoland\nPortugal\nNorway\nSlovakia\nX All products\nSlovenia\nX All products\nSpain\nSweden\nX All products\nUnited Kingdom",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eudn/2007/211/annex/I",
    "retrieved_at": "2026-11-01T15:17:14.014369+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}